Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Investor teach-in

2nd Apr 2015 14:00

RNS Number : 3346J
Venn Life Sciences Holdings PLC
02 April 2015
 

 

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

 

Investor teach-in

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, will be hosting a teach-in where Tony Richardson, CEO will provide an overview and strategy of the Company on Tuesday 21 April 2015. No new material trading or financial information will be disclosed.

 

The event is open to all investors and analysts and will be held from 16:30 until 19:30 in the Black Bar at Rocket Bar, 6 Adams Court, Old Broad Street, London, EC2N 1DX and will be followed by drinks and canapés.

 

To register for the event, please email [email protected] or call the Walbrook PR team below.

 

Enquiries:

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla Mc Guinness, Marketing Manager

 

Tel: +33 676 93 11 78

Zeus Capital (Nominated Adviser and Broker)

 

Ross Andrews/Andrew Jones

Tel: 0161 831 1512

Alex Davies

Tel: 020 7533 7727

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

 

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFLLFBEZFEBBX

Related Shares:

ORPH.L
FTSE 100 Latest
Value8,809.74
Change53.53